GLP-1 drugs like Ozempic and Wegovy were built to treat diabetes and obesity by suppressing appetite. What researchers are now finding is that the same mechanism appears to dial down cravings for alcohol, nicotine and other addictive substances too, and they think they finally know where in the brain that is happening.
ScienceDaily's coverage, drawn from an analysis in The Conversation, points to the lateral septum, a brain region historically associated with emotional regulation, as the likely site of this effect. The area carries a high density of GLP-1 receptors, integrates memory and spatial information arriving from the hippocampus, and contains place cells that respond strongly to reward, feeding signals directly into the brain's dopamine producing regions.
The Evidence Behind This
Human studies have already shown that GLP-1 agonists reduce alcohol consumption in people taking them for weight loss or diabetes, an effect initially treated as a curious side note rather than the main story. Animal studies go further, showing reduced use of cocaine, amphetamines, opiates and nicotine, and recent research specifically confirms that activating GLP-1 receptors in the lateral septum reduces both food and alcohol consumption in mice.
A Region With a Strange History
The Conversation's original analysis notes that the lateral septum first drew scientific attention back in 1953, when researchers Joseph Brady and Walle Nauta coined the term "septal rage" after observing sharply increased aggression in animals whose lateral septum had been damaged. Seven decades later, the same region is turning up as a potential control point for craving itself.
Why This Could Matter Well Beyond Weight Loss
If the lateral septum really is functioning as a general craving centre rather than something narrowly tied to appetite, that reframes an entire class of drugs already approved and in widespread use as a potential tool for addiction treatment, a use case that would require none of the years of drug development typically needed to bring a new compound to that point. It also means anyone already on these medications for weight loss may be experiencing effects on cravings well beyond food, whether they have noticed it or not.
Not Just a Side Effect Anymore
For years, reduced drinking or smoking among people taking GLP-1 drugs for weight loss was treated as an incidental, mildly interesting side note buried in trial data. Mapping the lateral septum as a specific mechanism changes that status considerably, turning an anecdotal pattern into something researchers can now design targeted studies around, rather than something they simply noticed happening to some patients along the way.
Ronny M (ronny76netstuff@gmail.com) is a content creator under the Newswav Creator programme, where you get to express yourself, be a citizen journalist, and at the same time monetize your content & reach millions of users on Newswav. Log in to creator.newswav.com and become a Newswav Creator now!
The User Content (as defined on Newswav Terms of Use) above including the views expressed and media (pictures, videos, citations etc) were submitted & posted by the author. Newswav is solely an aggregation platform that hosts the User Content. If you have any questions about the content, copyright or other issues of the work, please contact creator@newswav.com.
